" class="no-js "lang="en-US"> Christophe Douat - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Christophe Douat | PTF

Christophe Douat

About Christophe Douat

CEO of MedinCell

Related Story

Industry News

 EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments | PTF

EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments

November 24 2022

European Investment Bank (EIB), backed by the Investment Plan for Europe, and pharmaceutical company MedinCell, […]